How to Read a Third-Party COA

What is a third-party certificate of analysis?

A third-party certificate of analysis, often abbreviated as COA, is a laboratory document reporting analytical test results for a specific material, lot or batch. In peptide research, a COA commonly addresses identity, purity, assay, appearance and sometimes residual solvents, water content, counterion content, endotoxin or other quality attributes.

Third-party means the testing laboratory is separate from the supplier or manufacturer. This independence can strengthen documentation, but it does not automatically prove that a material is suitable for any specific experiment, regulatory purpose or human use.

The main task for researchers is to read the COA as evidence about a defined batch, generated by specified analytical methods, within stated limits. A COA should be evaluated alongside the experimental design, institutional requirements, chain-of-custody records and any applicable regulatory obligations.

Research Notice
This article discusses published scientific research. It is provided for educational purposes only and does not provide medical advice, dosing, administration or human-use instructions.

1. Confirm the laboratory, scope and batch traceability

Start with document identity. A usable third-party COA should identify the testing laboratory, report number, issue date, tested material name, lot or batch number, sample receipt date and the party that submitted the sample. The batch number on the COA should match the label, packing slip or internal receiving record exactly.

Look for the laboratory address, authorized signatory and, where applicable, accreditation details. ISO/IEC 17025 accreditation is relevant because it concerns laboratory competence for specified tests, but it must be read carefully. Accreditation for one method does not necessarily mean every method on the COA is within the accredited scope.

Traceability is especially important for peptides because similar names can refer to different salts, counterions, hydrate states, stereochemistry or sequence variants. A COA for one lot is not evidence for another lot, and a supplier summary page is not a substitute for lot-specific analytical documentation.

2. Read identity testing before purity numbers

Identity answers the question: is the material consistent with the stated molecule. For peptides, identity is often assessed using mass spectrometry, such as LC-MS or MALDI-TOF MS, which compares the observed molecular mass with the expected mass. This is chemical analytical evidence, not in vitro, animal, observational human, controlled human trial or authorised clinical-use evidence.

A credible identity section should report enough information to interpret the result. Useful details include expected molecular weight, observed mass, ion species where relevant and the analytical platform used. A result that simply says pass without method information is less informative.

Mass confirmation alone does not prove full structural correctness. Isomeric or closely related impurities, sequence deletions, oxidized forms, aggregation and counterion composition may require additional methods. For complex research materials, identity is best treated as a convergence of evidence rather than a single number.

3. Interpret peptide purity, assay and impurity results

Purity is commonly reported by HPLC or UPLC as area percent. In simple terms, the chromatogram separates detectable components, and the main peak area is expressed as a percentage of total integrated peak area. This does not always equal mass percent, biological activity or total content.

Assay is different from purity. Assay estimates the amount of target analyte present, often as a percent of label claim or as a measured concentration. A peptide can show high chromatographic purity while still having lower net peptide content because of water, salts, counterions or residual solvent.

Impurity reporting should list known and unknown impurities where the method is designed to detect them. In peptide analysis, relevant impurity categories can include truncated sequences, deletion peptides, deamidated forms, oxidized variants and synthesis-related residues. The COA should state whether impurity limits are supplier specifications, compendial limits, client-specified limits or method reporting outputs.

Water content, often measured by Karl Fischer titration, can materially affect net content calculations. Residual solvents may be assessed by gas chromatography, while inorganic residues may require methods such as ion chromatography or elemental analysis. Each method provides a different type of analytical evidence and should not be interpreted beyond its scope.

4. Check methods, specifications and acceptance criteria

A COA is easier to interpret when each test has a method reference, result, unit and acceptance criterion. Method references may point to internal laboratory methods, pharmacopeial chapters, validated client methods or recognized analytical procedures. If a method is internal, the COA may not disclose the full procedure, so the report should at least define the technique and measurement endpoint.

Acceptance criteria are the limits used to decide whether a result conforms. For example, a purity specification might state not less than a defined percentage by HPLC, while residual solvent limits may be reported in ppm. Researchers should distinguish between a numerical result and a pass or fail conclusion because both are needed for proper interpretation.

Validated analytical methods are generally assessed for characteristics such as specificity, accuracy, precision, linearity, range, detection limit, quantitation limit and robustness. These concepts are described in recognized analytical guidance such as ICH Q2 and related pharmacopeial resources. A routine COA usually summarizes results rather than presenting a full validation package.

Also check whether the result is reported as as is, dried basis, free base basis or salt basis. These distinctions can change how content is calculated. For peptides, counterions such as acetate or trifluoroacetate can influence the relationship between gross material weight and net peptide content.

5. Identify common COA red flags and limitations

Several warning signs should prompt further review. These include missing batch numbers, no laboratory identity, no test methods, altered formatting, inconsistent dates, mismatched product names, results without units or specifications and identity testing that lacks interpretable data. A very high purity number is not meaningful if the method and chromatogram are absent.

Another limitation is sample representativeness. A third-party lab tests the sample it receives, not every vial or container in a lot. Proper sampling, chain of custody and storage records help connect the tested sample to the material used in a research workflow.

COAs also do not replace experimental controls. Even when identity and purity are consistent with specifications, researchers still need appropriate blanks, positive controls where scientifically justified, stability checks and documentation of handling conditions. Analytical conformity is one part of research quality, not the entire quality system.

Researchers should be cautious with broad phrases such as research grade, high purity or tested by third party when they are not linked to specific data. Research Use Only or Not for Human Consumption labelling does not, by itself, establish regulatory status, suitability or exemption from applicable Canadian requirements.

6. Place the COA in a documentation workflow

For laboratory recordkeeping, save the COA with the purchase record, receiving log, storage record and experiment-specific notebook entry. Record the lot number in methods sections, internal inventory systems and any downstream sample preparation records. This helps connect analytical documentation to experimental reproducibility.

When comparing suppliers or lots, compare the same attributes using similar methods where possible. HPLC purity measured under one gradient, wavelength and column condition may not be directly comparable with another method. Differences in method sensitivity can produce different impurity profiles from the same material.

If a project has regulated, clinical, diagnostic or manufacturing implications, a standard supplier COA may be insufficient. Additional qualification, method transfer, audit review, stability data or regulatory documentation may be required depending on the use case and governing framework.

What Does the Research Show?

The relevant evidence base for reading a certificate of analysis is primarily analytical chemistry practice, laboratory accreditation standards and regulatory quality guidance. This is not in vitro, animal, observational human, controlled human trial or authorised clinical-use evidence, because a COA evaluates chemical and quality attributes of a batch rather than biological outcomes.

Analytical evidence: HPLC, UPLC, mass spectrometry, Karl Fischer titration, gas chromatography and related methods can characterize specific quality attributes when appropriately selected and validated.
Method guidance: recognized sources such as ICH analytical validation guidance, pharmacopeial chapters and ISO/IEC 17025 describe principles for method competence, validation and laboratory quality systems.
Limitations: a COA does not establish biological activity, clinical performance, human suitability or equivalence to any pharmaceutical product.
Research evidence separation: in vitro, animal or human research about a molecule, where it exists, does not verify the purity, identity or quality of a particular supplier lot.

A third-party COA is most useful when read as a structured analytical report. Researchers should verify traceability, understand the methods, separate purity from assay, examine specifications and document how the tested lot enters the research workflow.

Related Research Product

The Lux Peptides catalog includes BPC-157 as an example of a peptide catalog item for which lot-specific analytical documentation should be evaluated separately from molecule-level literature.

Educational Disclaimer
This article is provided for scientific and educational purposes only. It does not describe or imply the safety, effectiveness or intended use of any Lux Peptides product.
Nothing in this article is intended to diagnose, treat, cure or prevent disease or provide instructions for human use.